ArticleCureus2026
Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glucagon-like peptide-1 receptor agonists, including semaglutide and tirzepatide, are frequently prescribed for obesity management in non-diabetic patients. Euglycemic ketoacidosis has emerged as a concerning complication in this patient population, yet no study has directly compared ketoacidosis reporting signals between these two agents in non-diabetic patients using real-world pharmacovigilance data. Methods We conducted a retrospective disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database from January 2021 through December 2025. Following deduplication, reports were filtered for semaglutide and tirzepatide as primary suspect medications. Non-diabetic patients were identified by excluding reports with diabetes-related indications. Ketoacidosis cases were identified using MedDRA preferred terms. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals (CIs) were calculated for each drug. Results Following deduplication, 7,349,591 unique reports were analyzed. Among non-diabetic patients, 48,082 semaglutide and 98,295 tirzepatide reports were identified. Ketoacidosis was reported in 261 semaglutide cases and 209 tirzepatide cases. Semaglutide demonstrated a significant disproportionality signal (ROR 3.15, 95% CI 2.78-3.56; PRR 3.14, 95% CI 2.78-3.54). Tirzepatide also showed a significant but lower signal (ROR 1.22, 95% CI 1.06-1.39; PRR 1.21, 95% CI 1.06-1.39). Hospitalization was required in 74.3% and 71.3% of semaglutide and tirzepatide cases, respectively. Tirzepatide-associated reports showed a marked upward trend, increasing from 1-2 cases per quarter in 2022 to 28-34 cases per quarter by 2025. Conclusions Both semaglutide and tirzepatide are associated with significant ketoacidosis reporting signals in non-diabetic patients, with semaglutide demonstrating a higher disproportionality signal. The high rates of hospitalization and rapidly increasing tirzepatide reports highlight an emerging safety concern requiring clinical vigilance in patients using these agents for obesity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.